INOVIO Announces Pricing of $20.0 Million Public Offering

INOVIO Pharmaceuticals, Inc. has announced the pricing of an underwritten public offering aimed at raising approximately $20 million. The offering, which includes 21,052,632 shares of common stock priced at $0.95 per share, also features accompanying warrants that allow for the purchase of up to 42,105,264 additional shares. The transaction is expected to close on or about July 31, 2026, pending the fulfillment of customary closing conditions.

Based in Plymouth Meeting, Pennsylvania, INOVIO Pharmaceuticals specializes in developing DNA medicines to treat and prevent diseases related to human papillomavirus (HPV), cancer, and various infectious diseases. The company’s innovative approach utilizes DNA technology to enhance the body’s ability to produce its own therapeutic agents, positioning it at the forefront of the biotechnology sector. The funds raised from this public offering are anticipated to support ongoing research and development efforts, as well as to bolster the company’s operational capabilities.

The strategic rationale behind this offering is multifaceted. By securing additional capital, INOVIO aims to advance its clinical programs and potentially accelerate the commercialization of its therapies. The biotechnology sector has experienced significant growth, driven by increased demand for innovative treatments and a heightened focus on personalized medicine. INOVIO’s commitment to addressing unmet medical needs in oncology and infectious diseases aligns with broader industry trends emphasizing the importance of novel therapeutic solutions.

Piper Sandler is acting as the sole manager for this offering, which also includes an option for the underwriter to purchase up to an additional 3,157,894 shares within a 30-day period. This provision allows for potential flexibility in capital raising, depending on market conditions and investor interest. The public offering follows a shelf registration statement that was filed with the Securities and Exchange Commission earlier in July 2026, indicating a proactive approach to capital markets by INOVIO.

As the biotechnology landscape continues to evolve, public offerings such as INOVIO's reflect the sector's resilience and investors' appetite for innovative health solutions. The successful completion of this offering could enhance INOVIO’s financial position and facilitate further advancements in its product pipeline, contributing to the overall growth of the biotechnology industry. The implications of this transaction may resonate beyond INOVIO, potentially influencing investor sentiment and capital flows within the sector as companies seek to leverage public markets for funding.